Harmonizing patient-reported outcome measurements in inherited bleeding disorders with PROMIS

Evelien S. van Hoorn*, Lorynn Teela, Isolde A.R. Kuijlaars, Kathelijn Fischer, Samantha C. Gouw, Marjon H. Cnossen, Lotte Haverman, for SYMPHONY consortium and Dutch research group for PROMIS implementation in inherited bleeding disorders

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

2 Citations (Scopus)
49 Downloads (Pure)
Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalHaemophilia
Volume29
Issue number1
Early online date17 Nov 2022
DOIs
Publication statusPublished - Jan 2023

Bibliographical note

Funding Information:
The SYMPHONY consortium, which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. SYMPHONY aims to identify best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes e.g. Diagnostics (workpackage 3&4), Treatment (workpackages 5–9) and Fundamental Research (workpackages 10–12). This research received funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr M.H. Cnossen. Beneficiaries of the SYMPHONY consortium: Erasmus MC – Sophia Children's Hospital, University Medical Center Rotterdam, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL. The Dutch research group for PROMIS implementation in inherited bleeding disorders aims to research the feasibility, reliability and validity of Dutch PROMIS item banks in children and adults with inherited bleeding disorders. We would like to thank our colleagues Marjolein Peters, Michiel Coppens, Hester F. Lingsma, Marieke J.H.A. Kruip, Lize F.D. van Vulpen & Tessa C.M. van Gastel for their contribution to the Dutch research group for PROMIS implementation in inherited bleeding disorders.

Funding Information:
The SYMPHONY consortium, which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. SYMPHONY aims to identify best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes e.g. Diagnostics (workpackage 3&4), Treatment (workpackages 5–9) and Fundamental Research (workpackages 10–12). This research received funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA‐ORC Call grant agreement NWA.1160.18.038. Principal investigator: Dr M.H. Cnossen. Beneficiaries of the SYMPHONY consortium: Erasmus MC – Sophia Children's Hospital, University Medical Center Rotterdam, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL.

Cite this